Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance
Open accessThe DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
Abstract
Chemotherapy, radiotherapy, targeted therapy, and immunotherapy are established cancer treatment modalities that are widely used due to their demonstrated efficacy against tumors and favorable safety profiles or tolerability. Nevertheless, treatment resistance continues to be one of the most pressing unsolved conundrums in cancer treatment. Hypoxia-inducible factors (HIFs) are a family of transcription factors that regulate cellular responses to hypoxia by activating genes involved in various adaptations, including erythropoiesis, glucose metabolism, angiogenesis, cell proliferation, and apoptosis. Despite this critical function, overexpression of HIFs has been observed in numerous cancers, leading to resistance to therapy and disease progression. In recent years, much effort has been poured into developing innovative cancer treatments that target the HIF pathway. Combining HIF inhibitors with current cancer therapies to increase anti-tumor activity and diminish treatment resistance is one strategy for combating therapeutic resistance. This review focuses on how HIF inhibitors could be applied in conjunction with current cancer treatments, including those now being evaluated in clinical trials, to usher in a new era of cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“as hypoxia is known to contribute to immunosuppression and ICI resistance, targeting hypoxia may also enhance the effectiveness of immunotherapies [215].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693 · cited 1×
“Despite HIF-1α and HIF-2α sharing similar abilities to dimerize with HIF-β, bind to genes whose promoters containing the HRE motif, and activate downstream expression of hypoxia-inducible genes, they differ in expression levels during different timings in cancer progression [24].”
BackgroundHIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335
Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors
Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00115-1 · Cited by 996
Research works printed but not linked: 5
- Fallah J, Rini BI. HIF inhibitors: status of current clinical development. Curr Oncol Rep. 2019;21(1):6. · DOI · Paper page
- Sun Y, Guan Z, Liang L, Cheng Y, Zhou J, Li J, et al. HIF-1alpha/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer. Oncol Rep. 2016;35(3):1549–56. · DOI
- Noman MZ, Hasmim M, Lequeux A, Xiao M, Duhem C, Chouaib S, et al. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. Cells. 2019;8(9):1083. · DOI · Paper page
- Martínez-Sáez O, Gajate Borau P, Alonso-Gordoa T, Molina-Cerrillo J, Grande E. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy. Crit Rev Oncol Hematol. 2017;111:117–23. · DOI
- Zhang T, Zhu X, Wu H, Jiang K, Zhao G, Shaukat A, et al. Targeting the ROS/PI3K/AKT/HIF-1alpha/HK2 axis of breast cancer cells: Combined administration of Polydatin and 2-Deoxy-d-glucose. J Cell Mol Med. 2019;23(5):3711–23. · DOI
Cited by
Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities
Beckers, C., Pruschy, M., & Vetrugno, I. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.006 · Cited by 167
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Additionally, as hypoxia is known to contribute to immunosuppression and ICI resistance, targeting hypoxia may also enhance the effectiveness of immunotherapies [215].”
Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence
Tufail, M., Jiang, C., & Li, N. (2025) · Military Medical Research · doi:10.1186/s40779-025-00595-2 · Cited by 97
Natural products reverse cisplatin resistance in the hypoxic tumor microenvironment
Yang, C., Deng, X., Tang, Y., Tang, H., & Xia, C. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217116 · Cited by 70
Chen, Y., Bai, M., Liu, M., Zhang, Z., Jiang, C., Li, K., Chen, Y., Xu, Y., & Wu, L. (2025) · Cancer Medicine · doi:10.1002/cam4.71317 · Cited by 72
Metadata
- Authors
- Kao, T.-W., Bai, G.-H., Wang, T.-L., Shih, I.-M., Chuang, C.-M., Lo, C.-L., Tsai, M.-C., Chiu, L.-Y., Lin, C.-C., & Shen, Y.-A.
- Affiliations
- Taipei Medical University (TW)
- National Taiwan University (TW)
- Johns Hopkins University (US)
- National Yang Ming Chiao Tung University (TW)
- Taipei Medical University Hospital (TW)
- Mackay Memorial Hospital (TW)
- Corresponding author
- Shen, Yao-An
- ORCID
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2023-07-18
- Volume
- 42
- Issue
- 1
- Pages
- 171-171
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- PMC
- PMC10353250
- OpenAlex
- W4384627173
- Cited by
- 89
- References
- 171
- Citations by year
- 2026: 20 · 2025: 30 · 2024: 36 · 2023: 3
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Taipei Medical University (TMU108-AE1-B12)
- Ministry of Science and Technology, Taiwan (MOST 109-2314-B-038-021-MY3)
- National Science and Technology Council, Taiwan (NSTC 111-2622-B-038-008, NSTC 112-2823-8-038-001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- hypoxia-inducible factor, HIF inhibitors, cancer therapy resistance, combination therapy, tumor hypoxia, angiogenesis, glucose metabolism, erythropoiesis, apoptosis, chemoresistance, radiotherapy resistance, targeted therapy, immunotherapy
- MeSH terms
- Hypoxia, Humans, Neoplasms, Cell Hypoxia, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance. https://app.cochat.ai/papers/10.1186/s13046-023-02724-y
- The paper
- Kao, T.-W., Bai, G.-H., Wang, T.-L., Shih, I.-M., Chuang, C.-M., Lo, C.-L., Tsai, M.-C., Chiu, L.-Y., Lin, C.-C., & Shen, Y.-A. (2023). Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-023-02724-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.